Select country change
Shopping cart (0 , 0,00 ) Menu Search
Distributed product

SDMA ELISA

  • Regulatory status:RUO
  • Type:Competitive ELISA, Immobilized antigen
  • Other names:Symmetric Dimethylarginine
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


REA203/96 96 wells (1 kit)
PubMed Product Details
Technical Data

Type

Competitive ELISA, Immobilized antigen

Applications

Serum, Plasma-EDTA

Sample Requirements

20 μl/well

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

Store the complete kit at 2–8°C. Under these conditions, the kit is stable until the expiration date (see label on the box).

Calibration Range

0.2–3.0 µmol/l

Limit of Detection

0.03 μmol/l

Summary

Features

  • For in vitro use only.
  • Disposable gloves should be used.
  • Material of animal origin used in the preparation of the kit has been obtained from animals certified as healthy but these materiále should be handled as potentially infectious.

Research topic

Blood pressure regulation and NO metabolism

Summary

SDMA is eliminated from the body exclusively by renal excretion; therefore SDMA plasma concentration is tightly related to renal function. Elevated SDMA levels may prospectively indicate future risk of cardiovascular disease and mortality independently of the level of renal impairment.

References to Product

References

  • Bode-Boger SM, Scalera F, Kielstein JT, Martens-Lobenhoffer J, Breithardt G, Fobker M, Reinecke H. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J Am Soc Nephrol. 2006 Apr;17 (4):1128-34
  • Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function--a meta-analysis. Nephrol Dial Transplant. 2006 Sep;21 (9):2446-51
  • Wanby P, Teerlink T, Brudin L, Brattstrom L, Nilsson I, Palmqvist P, Carlsson M. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis. 2006 Apr;185 (2):271-7
Related Products Documents